The new drug has already passed Phase 1 safety trials in humans, making it a "strong candidate" for future PTSD treatments.

A new study reveals that astrocyte-derived GABA, not neuronal activity, plays a central role in PTSD by impairing the brain’s ability to extinguish traumatic memories.